All In MedTech

FDA Clearance Tracker · P150013-S007

PD-L1 IHC 22C3 pharmDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 20, 2017

Approved

Time to decision

60 days

Received Sep 21, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P150013-S007
Device name
PD-L1 IHC 22C3 pharmDx
Applicant location
Santa Clara, CA
Received
Sep 21, 2017
Decided
Nov 20, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P150013

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approved for labeling changes to include results from additional non-clinical studies.

Source documents

Other decisions for Agilent Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.